To help labs get the answers they so desperately need, The Dark Intelligence Group has launched the COVID-19 STAT Intelligence Briefings Service.
During this disruptive SARS-CoV-2 pandemic, TDIG has created this free intelligence service with a total focus on COVID-19 and everything labs need to meet the business challenges of the pandemic, including the latest on rapid molecular serology COVID-19 testing, with sources and supply chain updates; How labs are getting paid for COVID-19 by Medicare, Medicaid, and private health plans; and Daily updates on changes to federal regulations and directives from the FDA, CDC, and CMS.
COVID-19 STAT Intelligence Briefings service updates daily. It includes briefings, interviews with leading subject matter experts, podcasts and webinars, plus timely analysis of the daily changes in the pandemic.
It is all actionable information, supplemented with real-time national lab test dashboards fed with data from TDIG partners at XIFIN, Visiun, and hc1.com.
COVID-19 STAT Intelligence Briefings is also introducing twice-weekly conference calls, so attendees can hear updates from nationally known thought leaders and get critical questions answered on managing their laboratories during the SARS-CoV-2 outbreak.
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
hVIVO reports positive results from RSV antiviral human challenge trial
Amyris enters agreement with BioMaP-C
Avidity Biosciences reports partial clinical hold on delpacibart etedesiran lifted
UroGen Pharma doses first patient in Phase 3 trial of UGN-103 for bladder cancer
Brain+ launches Ayla CST Assistant following UK regulatory approval
Advicenne's ADV7103 achieves regulatory milestones in the US
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment